*THIS IS AN EXCLUSIVE 80% EQUITY SHARE DIVESTMENT ADVERTISEMENT FOR A STRATEGIC HEALTHCARE TECHNOLOGY COMPANY*
- *COMPANY HEADQUARTERS:* Turkey (All international operations are managed via the corporate entity legally established in Turkey
- *TERRITORY SCOPE:* Turkey, Japan, Russia, Azerbaijan, and Kazakhstan (5 Countries)
- *DISTRIBUTION TENURE: 5-Year Exclusive Regional Market Monopoly* tethered via the principal manufacturer agreement (With an extendable/renewable option upon expiry).
- *PRODUCT PROFILE:* Globally certified with *FDA, CE (MDR), and ISO* medical standards; a highly proprietary healthcare technology that holds an *ABSOLUTE GLOBAL MONOPOLY (PEERLESS/WITHOUT COMPETITION)* in its specific segment.
- *TRANSACTION STRUCTURE: 80% Majority Share Divestment (Share Deal)* structured under an Anonymous Company (A.Ş.) corporate format.
*FINANCIAL POTENTIAL AND MARKET LEVERAGE*
The underlying business model leverages exceptional net margins generated through primary product placements and compounding annuity streams from ancillary product volume:
- *PRIMARY PRODUCT PROFITABILITY: $12,000 USD Net Profit per unit sold.*
- *ANCILLARY PRODUCT PROFITABILITY: $500 USD Net Profit per pack.* (Each active primary unit carries a documented baseline consumption average of 40 ancillary units per annum. Consequently, every primary placement underwrites an *additional recurring net profit annuity of $20,000 USD per year).*
Under the active regional deployment frameworks, the *Year 1 volume target is set at 4,500 primary units, securely underwriting a Total Projected Year 1 Net Profit of $144,000,000 USD.*
**TRANSACTION PROTOCOL AND GOVERNANCE*
1. *GOVERNANCE STRUCTURE & TRANSITION:* The transaction encompasses the absolute transfer of *80% majority equity control.* To safeguard the strategic institutional network and seamlessly guide the incoming executive team through operational onboarding, the founding partner will retain a *20% minority stake.* It is a strict prerequisite of the Share Purchase Agreement (SPA) that the founder will serve on the Board of Directors as a "Strategic Government Relations Advisor" for a *maximum period of 1 (one) year.* Upon completion of this 1-year orientation phase, active corporate duties will cease, while the 20% equity ownership and dividend rights will remain permanently active.
2. *REGULATORY COMPLIANCE STATUS:* The technology commands active FDA, CE, and ISO approvals. It possesses a verified technical baseline in Turkey via prior UTS (Medical Device Tracking System) registration; the purchasing entity can fully re-activate import operations within a standard 30-day corporate window. The unexploited regulatory status across the remaining 4 jurisdictions offers the incoming investor a massive structural lever to shape local monopolies entirely under their own corporate umbrella.
3. *STRICT REJECTION PROTOCOL:* Requests for physical machinery samples, field demonstrations, testing trial phases, or non-liquid equity-swap propositions *will be strictly and instantly rejected.* The acquiring group is not purchasing a physical consumer commodity; they are acquiring a registered *5-year exclusive market monopoly across 5 nations* backed by an operating corporate chassis. Clinical efficacy and global peer-reviewed trial indices are permanently established in medical literature.
4. *CONFIDENTIALITY FILTER:* To insulate commercial secrets and proprietary assets, corporate credentials, financial ledgers, and original distribution charters will be disclosed exclusively to qualified buyers who execute a *highly restrictive, legally binding Non-Disclosure Agreement (NDA)* backed by an institutional *Letter of Intent (LOI)* or verified Proof of Funds.
5. *DEBT-FREE TRANSACTION:* The transaction will be finalized as a clean equity transfer. All existing corporate liabilities, debt obligations, or financial encumbrances of the company will be legally and proportionally deducted from the final acquisition price based on the 80% equity ratio, delivering a debt-free asset at closing.
6. *EXCLUSIVE TURKISH LANGUAGE NEGOTIATION MANDATE:* To optimize operational speed and ensure prompt alignment, *all communications, initial intake messages, formal meetings, legal negotiations, and contract drafting will be conducted EXCLUSIVELY IN THE TURKISH LANGUAGE.* It is an absolute, non-negotiable prerequisite that investing groups or international funds engage with us solely through legal counsels, attorneys, or corporate finance advisors who possess absolute, native-level fluency in Turkish. Communications initiated in any other language will be summarily disregarded.
*IMPORTANT NOTICE:*
Qualified institutional buyers and family offices are requested to initiate formal contact *EXCLUSIVELY via MESSAGE and EXCLUSIVELY IN THE TURKISH LANGUAGE* through their designated company officials or legal counsels. Any attempts to contact via phone or other channels will be summarily ignored.
